Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023
- Odyssey is set to hold its Annual Meeting of Stockholders on January 12, 2023
- The meeting promises an excellent podium to update shareholders on the company’s progress throughout the 2022 calendar year as well as its plans for the future
- Odyssey has so far achieved vital milestones such as progress in its ONP-002 novel compound on the treatment of concussions, patent protection filing for its Nasal Device, and the expansion of its executive team
- It looks to take advantage of the meeting to draw stockholders’ views and opinions on specific topics while also offering them a platform to contribute to the company’s decision-making for the 2023 calendar year
- Odyssey is optimistic about its future, and through its research and product development, it looks to tap into the concussion market, projected to hit $9.3 billion by 2028
Odyssey Health (OTC: ODYY), a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, just announced plans to hold its Annual Meeting of Stockholders, scheduled for January 12, 2023. The meeting will be an excellent platform for the company and its management to update its stockholders on the progress made throughout 2022 and its plans for the future (https://nnw.fm/kcRm3 ).
Odyssey, so far, has achieved critical milestones, among them decentd progress on research on its ONP-002 novel compound for the treatment of concussions. In-vivo animal testing has shown ONP-002 to have anti-inflammatory, antioxidant, and antiedematous properties that ensure it eliminates the immediate consequences of a concussion, such as oxidative stress, swelling, and inflammation in the brain. It also does so while also restoring proper blood flow. In addition, further animal studies on the novel compound showed that it reduced behavioral pathology associated with mild traumatic brain injury (“mTBI”) symptoms that include motor/sensory performance, anxiety, and memory impairment (https://nnw.fm/Amx6G ).
The recently-completed phase I study on concussion treatment, which showed that ONP-002 was safe and well-tolerated among the test group, used Odyssey’s Nasal Device and drug combination. Its management expressed its pleasure in the functionality and performance of the device in the administration of the ONP-002 novel compound, lauding its ability to get drugs for neurological conditions delivered directly into the brain (https://nnw.fm/JasF9). Odyssey has since filed for patent protection on the device, which it is confident provides an opportunity and advantage for treating neurological conditions (https://nnw.fm/AqfNM ).
Odyssey has also expanded its executive team with the introduction of Odyssey Neuropharma’s new Chief Commercial Officer (“CCO”), Erik Emerson, and Chief Operating Officer (“COO”), Greg Gironda. They will drive the company toward market readiness (https://nnw.fm/yTTtq ).
The 2023 Annual Meeting of Stockholders promises an important podium to discuss the company’s future. It will allow stockholders to lend their views and opinions on specific topics and contribute to the company’s decision-making for the 2023 calendar year. Odyssey’s management hopes the stockholders’ contributions will help push the company forward, even as they work towards creating more shareholder value with aggressive market expansion and advancements in the ongoing and future clinical studies.
Odyssey’s management, led by CEO Michael Redmond, remains confident about the company’s future, recognizing the growing opportunities in the medical sector and the high unmet need for treating concussions. The concussion market is expected to hit $9.3 billion by 2028, up from $7.2 billion in 2021, representing a CAGR of 3.7%. Odyssey looks to tap into this growth and grow its shareholder value while at it (https://nnw.fm/0EBX6 ).
For more information, visit the company’s website at www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://nnw.fm/ODYY
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Odyssey is set to hold its Annual Meeting of Stockholders on January 12, 2023
- The meeting promises an excellent podium to update shareholders on the company’s progress throughout the 2022 calendar year as well as its plans for the future
- Odyssey has so far achieved vital milestones such as progress in its ONP-002 novel compound on the treatment of concussions, patent protection filing for its Nasal Device, and the expansion of its executive team
- It looks to take advantage of the meeting to draw stockholders’ views and opinions on specific topics while also offering them a platform to contribute to the company’s decision-making for the 2023 calendar year
- Odyssey is optimistic about its future, and through its research and product development, it looks to tap into the concussion market, projected to hit $9.3 billion by 2028
Odyssey Health (OTC: ODYY), a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, just announced plans to hold its Annual Meeting of Stockholders, scheduled for January 12, 2023. The meeting will be an excellent platform for the company and its management to update its stockholders on the progress made throughout 2022 and its plans for the future (https://nnw.fm/kcRm3 ).
Odyssey, so far, has achieved critical milestones, among them decentd progress on research on its ONP-002 novel compound for the treatment of concussions. In-vivo animal testing has shown ONP-002 to have anti-inflammatory, antioxidant, and antiedematous properties that ensure it eliminates the immediate consequences of a concussion, such as oxidative stress, swelling, and inflammation in the brain. It also does so while also restoring proper blood flow. In addition, further animal studies on the novel compound showed that it reduced behavioral pathology associated with mild traumatic brain injury (“mTBI”) symptoms that include motor/sensory performance, anxiety, and memory impairment (https://nnw.fm/Amx6G ).
The recently-completed phase I study on concussion treatment, which showed that ONP-002 was safe and well-tolerated among the test group, used Odyssey’s Nasal Device and drug combination. Its management expressed its pleasure in the functionality and performance of the device in the administration of the ONP-002 novel compound, lauding its ability to get drugs for neurological conditions delivered directly into the brain (https://nnw.fm/JasF9). Odyssey has since filed for patent protection on the device, which it is confident provides an opportunity and advantage for treating neurological conditions (https://nnw.fm/AqfNM ).
Odyssey has also expanded its executive team with the introduction of Odyssey Neuropharma’s new Chief Commercial Officer (“CCO”), Erik Emerson, and Chief Operating Officer (“COO”), Greg Gironda. They will drive the company toward market readiness (https://nnw.fm/yTTtq ).
The 2023 Annual Meeting of Stockholders promises an important podium to discuss the company’s future. It will allow stockholders to lend their views and opinions on specific topics and contribute to the company’s decision-making for the 2023 calendar year. Odyssey’s management hopes the stockholders’ contributions will help push the company forward, even as they work towards creating more shareholder value with aggressive market expansion and advancements in the ongoing and future clinical studies.
Odyssey’s management, led by CEO Michael Redmond, remains confident about the company’s future, recognizing the growing opportunities in the medical sector and the high unmet need for treating concussions. The concussion market is expected to hit $9.3 billion by 2028, up from $7.2 billion in 2021, representing a CAGR of 3.7%. Odyssey looks to tap into this growth and grow its shareholder value while at it (https://nnw.fm/0EBX6 ).
For more information, visit the company’s website at www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://nnw.fm/ODYY
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
